Loading clinical trials...

COMPLETEDPHASE3

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type

NCT00105547•Myrexis Inc.

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of dosing.

Detailed Description

This trial is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of MPC-7869 to placebo. The study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months. The primary objective of the study is to evaluate the change in cognition and activities of daily living.

Eligibility

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have had a diagnosis of probable Alzheimer's disease.
•Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
•Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
•Ability to read and understand English or Spanish to ensure compliance with cognitive testing and study visit procedures.
•Female subjects must be surgically sterile or postmenopausal for \> 1 year.
•Subjects currently taking approved medication for Alzheimer's disease for at least six months prior to day 1 may be enrolled.
•Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.

Exclusion Criteria

•Current evidence of other causes of dementia.
•History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
•Chronic or acute renal, hepatic or metabolic disorder.
•Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
•Major surgery and related complications not resolved within 12 weeks prior to Day 1.

Locations (132)

Alabaster, Alabama, United States

Huntsville, Alabama, United States

Mesa, Arizona, United States

Peoria, Arizona, United States

Phoenix, Arizona, United States

Sun City, Arizona, United States

Tucson, Arizona, United States

Little Rock, Arkansas, United States

Fresno, California, United States

Irvine, California, United States

Key Dates

Start Date

February 1, 2005

Completion Date

May 1, 2008

Last Updated

May 5, 2009

Enrollment

1,600

ACTUAL participants

Conditions

Alzheimer DiseaseDementia

Interventions

MPC-7869

DRUG

MPC-7869

DRUG

[18F]F-DOPA Imaging in Patients With Autonomic Failure

NCT04246437

Autonomic FailurePure Autonomic Failure+3 more

View study

RECRUITINGNA

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

NCT07178210

Alzheimer DiseaseLymphatic Obstruction

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 5, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Inclusion Criteria

Exclusion Criteria

[18F]F-DOPA Imaging in Patients With Autonomic Failure

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function